Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis by Manetti, Mirko et al.
IJAE 
Vo l .  116 ,  n .  1  (Supp lem ent) :  10 8 ,  2011
© 2011 Firenze University Press 
ht tp://www.fupress .com/ijae
ITALIAN JOURNAL OF ANATOMY AND EMBRYOLOGY
overexpression of vegF165b, an inhibitory splice variant 
of vascular endothelial growth factor, leads to insuﬃ  cient 
angiogenesis in patients with systemic sclerosis
Mirko  Manetti1, Serena  Guiducci2, Eloisa  Romano2, Claudia  Ceccarelli2, Marco  Matucci-Cerinic2, 
Lidia  Ibba-Manneschi1
1 Department of Anatomy, Histology and Forensic Medicine, University of Florence, Florence, Italy
2 Department of Biomedicine, Division of Rheumatology, University of Florence, Florence, Italy
Systemic sclerosis (SSc) is a chronic connective tissue disorder characterized by 
widespread microangiopathy, fi brosis, and autoimmunity that aff ects the skin and 
internal organs. Although in SSc there is a lack of suffi  cient angiogenic response to 
chronic tissue ischemia culminating in the loss of capillary vessels, the expression 
of vascular endothelial growth factor-A (VEGF) has paradoxically been shown to be 
upregulated in SSc skin and circulation. However, previous studies in the fi eld did 
not distinguish between the proangiogenic VEGF165 and antiangiogenic VEGF165b iso-
forms that are generated by alternative splicing in the terminal exon of VEGF pre-
RNA. In the present study, we investigated whether VEGF isoform expression could 
be altered in skin and circulation of SSc patients. Using RT-PCR, quantitative real-
time PCR, Western blotting, immunohistochemistry and confocal microscopy, we 
could show that the VEGF165b splice variant was selectively overexpressed at both the 
mRNA and protein levels in SSc skin. Elevated VEGF165b expression correlated with 
increased expression of profi brotic transforming growth factor-β1 (TGF-β1) and ser-
ine/arginine protein 55 (SRp55) splicing factor in keratinocytes, fi broblasts, endotheli-
al cells, and perivascular inﬂ ammatory cells. ELISA on plasma samples revealed that 
circulating levels of VEGF165b were signifi cantly higher in SSc patients than in control 
subjects. Microvascular endothelial cells (MVECs) isolated from SSc skin expressed 
and released higher levels of VEGF165b than healthy MVECs (H-MVECs). TGF-β1 
upregulated the expression of VEGF165b and SRp55 in both SSc- and H-MVECs. In 
SSc-MVECs, VEGF receptor-2 (VEGFR-2) was overexpressed, but its phosphorylation 
and ERK1/2 downstream signaling were impaired. Recombinant human VEGF165b 
and SSc-MVEC–conditioned medium inhibited VEGF165-mediated VEGFR-2 phospho-
rylation, ERK1/2 activation and capillary morphogenesis on Matrigel in H-MVECs. 
The addition of anti-VEGF165b blocking antibodies abrogated the antiangiogenic eff ect 
of SSc-MVEC–conditioned medium. Capillary morphogenesis was severely impaired 
in SSc-MVECs and could be ameliorated by treatment with recombinant VEGF165 and 
anti-VEGF165b blocking antibodies. In SSc, a switch from proangiogenic to antiangio-
genic VEGF isoforms may have a crucial role in the insuffi  cient angiogenic response 
to chronic ischemia. The combination of proangiogenic VEGF165 administration and 
VEGF165b neutralization might represent a potential therapeutic strategy to promote 
eff ective angiogenesis and capillary regeneration in SSc.
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